BioSpace News Archive

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today unveiled its new brand identity rooted in the company’s guiding principles of commitment, innovation and community which are signified by three interconnected rings.

T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) Patients can conveniently opt to visit one of nearly 2,000 Labcorp sites or arrange for a mobile phlebotomy service at their home

Seasoned Industry Veteran Brings Over 20 Years of Biotechnology and Pharmaceutical Development Experience, With Deep Expertise in Development of Ophthalmology Drugs Previously Served in Executive Leadership Roles at BridgeBio Pharma, Clearside Biomedical and Alcon, formerly the Ophthalmology subsidiary of Novartis

First FDA-Approved OTC Preservative-Free Antihistamine Eye Drop Approved for Relief of Itchy Eyes Associated with Allergies Now Rolling out to Major U.S. Retailers

MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows.

Exclusive license agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of pimasertib and MSC2015103B Day One plans to evaluate the combination of pimasertib and DAY101, the Company’s clinical-stage pan-RAF kinase inhibitor, in patients ≥12 years of age with advanced solid tumors

Ocugen, Inc. announced that on the recommendation of the European Medicines Agency, the European Commission has granted orphan medicinal product designation for OCU400, for the treatment of both retinitis pigmentosa and Leber Congenital amaurosis.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the Cowen 41 st Annual Health Care Conference on Tuesday, March 2, 2021, at 11:50 a.m. ET.

The global LIMS market is projected to witness a substantial growth during the tenure of 2019 to 2029.

BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing round, expanding our institutional shareholder base.